Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice

• DOI: 10.1086/600108
• Publication Date: 2009-06-22T20:02:39Z
• Authors: Lia M. Haynes; Hayat Caidi; Gertrud U. Radu; Congrong Miao; Jennifer L. Harcourt; Ralph A. Tripp; Larry J. Anderson
• Keywords: Pneumovirinae

Because the G protein of respiratory syncytial virus (RSV) has a CX3C chemokine motif that been associated with ability RSV to modulate virus-induced host immune response, we examined whether therapeutic treatment an anti-RSV monoclonal antibody (mAb), 131-2G, blocks CX3C-associated activity might decrease pulmonary inflammation infection in BALB/c mice. The results show mAb 131-2G on day 3 after reduces both and titer lungs. Later administration (day 5 infection) effectively reduced viral but had minimal effect inflammation. This study suggests be effective antiviral, either alone or combination F neutralizing antibodies, for decreasing response improve outcome.